Survival data confirm the value of Astellas’s FLT3-targeting approach in acute myelogenous leukaemia.
For Urovant, beating placebo in a pivotal trial of vibegron was the easy part.
Six months after floating, Urovant is gearing up to release pivotal data on its most advanced overactive bladder project.
Funds backed by drugmakers remain visible contributors to the venture world, but several of the big corporate names seem to have reined in spending.
Results of the prostate cancer project’s pivotal Aramis trial, already known to be positive, are presented for the first time.
Merck & Co awaits full Keynote-426 data with Keytruda plus Inlyta, while Seattle Genetics looks beyond Adcetris with enfortumab vedotin.
An upcoming Icer report will put the spotlight on unjustified price increases even as signs of moderation emerge.
But Erleada, Johnson & Johnson’s next-gen prostate cancer therapy, still needs to outperform the incumbent, Zytiga.
After years in the wilderness acute myeloid leukaemia is seeing a wave of activity, and there could be more targeted agents to come.